Jiuqiang Bio: First Quarter Report of 2026
Beijing Jiuqiang Biotechnology Co., Ltd. 2026 First Quarter Report
Securities code: 300406 Securities abbreviation: Jiuqiang Biotech Announcement number: 2026-039 Bond code: 123150 Bond abbreviation: Jiuqiang Convertible Bonds
Beijing Jiuqiang Biotechnology Co., Ltd.
2026 First Quarter Report
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions. Important content reminder:
The board of directors, directors and senior managers guarantee that the quarterly report is true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability.
The person in charge of the company, the person in charge of accounting work and the person in charge of the accounting department (accounting supervisor) declare that they guarantee the authenticity, accuracy and completeness of the financial information in the quarterly report.
Whether the first quarter financial accounting report has been audited
□Yes No
Beijing Jiuqiang Biotechnology Co., Ltd. 2026 First Quarter Report
1. Main financial data
(1) Main accounting data and financial indicators
Whether the company needs to retroactively adjust or restate previous years’ accounting data
□Yes No
This reporting period is better than the same period last year. This reporting period is better than the same period last year.
Increase or decrease (%) operating income (yuan) 334,810,688.09 319,809,793.71 4.69% Net profit attributable to shareholders of listed companies (yuan) 105,607,356.33 83,257,495.41 26.84% Net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses
102,997,864.98 82,322,050.62 25.12% net profit (yuan)
Net cash flow generated from operating activities (yuan) 95,506,236.76 70,946,714.51 34.62% Basic earnings per share (yuan/share) 0.18 0.14 28.57% Diluted earnings per share (yuan/share) 0.18 0.14 28.57% Weighted average return on equity 2.74% 1.99% 0.75% at the end of this reporting period compared with the end of the previous year at the end of this reporting period at the end of the previous year
Final increase or decrease (%) Total assets (yuan) 5,183,261,234.14 5,052,431,193.49 2.59% Owner’s equity attributable to shareholders of listed companies (yuan) 3,891,389,331.11 3,788,015,483.72 2.73%
(2) Non-recurring profit and loss items and amounts
Applicable □Not applicable
Unit: Yuan
Item Amount for this reporting period Description
Profit and loss from disposal of non-current assets (including the write-off of asset impairment provisions) -77,063.71
Government subsidies included in current profits and losses (closely related to the company’s normal business operations and in compliance with
National policy provisions, enjoyment in accordance with determined standards, and continuous impact on the company's profits and losses 3,106,311.02
(Except for government subsidies)
Other non-operating income and expenses other than the above items 42,035.35
Less: Impact on income tax 460,623.45
Amount of impact on minority shareholders’ equity (after tax) 1,167.86
Total 2,609,491.35 --
Details of other profit and loss items that meet the definition of non-recurring profits and losses
□Applicable Not applicable
The company has no other specific circumstances of profit and loss items that meet the definition of non-recurring profits and losses.
Explanation on defining the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Profit and Loss" as recurring profit and loss items
□Applicable Not applicable
The company does not define the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Profit and Loss" as recurring profit and loss items.
(3) Changes in major accounting data and financial indicators and their reasons
Applicable □Not applicable
Beijing Jiuqiang Biotechnology Co., Ltd. 2026 First Quarter Report
balance sheet items
Unit: Yuan
Statement items Closing balance Opening balance Change ratio Main reason
Prepayments 30,963,192.18 22,043,463.77 40.46% Mainly due to the increase in prepayments for purchases
Other current assets 3,649,643.53 55,515,461.22 -93.43% Contract liabilities resulting from redemption of one-year certificate of deposit due in Maixin 22,790,270.18 11,290,208.06 101.86% Mainly due to the increase in advance payments
Employee benefits payable 13,680,736.23 41,324,197.12 -66.89% Due to payment of bonuses
Other payables 34,156,084.64 4,294,868.57 695.28% Increase in expenses payable
Non-current liabilities due within one year 13,874,549.01 9,681,939.15 43.30% Reclassification of interest payable on convertible bonds
Other comprehensive income 43,956.94 297,912.88 -85.25% Income statement items caused by decrease in translation differences of foreign currency financial statements
Unit: Yuan statement item Current reporting period Same period last year Year-on-year increase or decrease Main reasons
Maixin received government subsidies in this period and had other income compared with the same period last year 3,106,311.02 1,884,693.31 64.82%
increased
Investment income (losses are marked with "-"
3,665,217.16 -152,998.11 2495.60% caused by interest on Maixin large-denomination certificate of deposit
Fill in the column)
Asset disposal income (losses are represented by “-”) Maixin’s asset disposal losses for this period increased compared with the same period last year.
-77,063.71 -750,180.00 89.73%
No. fill in the column) dropped
Non-operating income 46,413.88 12,347.51 275.90% Non-operating expenses caused by receiving reagents from suppliers in the current period 4,378.53 44,715.92 -90.21% Mainly due to the year-on-year decrease in external donation expenses. Net amount of other comprehensive income after tax -338,607.93 -35,824.27 -845.19% Due to the decrease in translation differences of foreign currency financial statements
2. Shareholder information
(1) The total number of common shareholders, the number of preferred shareholders whose voting rights have been restored, and the shareholding status of the top ten shareholders
Unit: Share Total number of common shareholders at the end of the reporting period 21,242 Total number of preference shareholders whose voting rights were restored at the end of the reporting period (if any) 0 Shareholding status of the top 10 shareholders (excluding shares lent through refinancing)
Shareholding ratio Holding of sales restrictions Pledge, mark or freeze Name of shareholder Nature of shareholder Number of shares held
(%) Number of shares Share status Quantity China Pharmaceutical Investment
State-owned legal person 18.49% 108,418,487 0 Not applicable 0 Limited company
Liu Xi Domestic natural person 11.43% 67,013,676 50,260,257 Not applicable 0 Luo Aiping Domestic natural person 9.72% 56,977,777 42,733,333 Not applicable 0 Sun Xiaolin Overseas natural person 8.59% 50,391,452 37,793,589 Not applicable 0 Zou Zuojun Domestic natural person 6.70% 39,280,659 29,460,494 Not applicable 0 ZHOU XIAOYAN Overseas natural person 5.00% 29,315,336 0 Not applicable 0 Cheng Hui Domestic natural person 2.45% 14,349,483 0 Not applicable 0 #Liu Shaoluan Domestic natural person 1.10% 6,431,885 0 Not applicable 0Chen Hui Domestic natural person 0.84% 4,930,000 0 Not applicable 0
Beijing Jiuqiang Biotechnology Co., Ltd. 2026 First Quarter Report
Hong Kong Securities Clearing Company
Overseas legal person 0.57% 3,347,982 0 Not applicable 0 Limited company
Shareholdings of the top 10 shareholders without sales restrictions (excluding shares lent through refinancing and shares locked by executives)
Share type
Name of shareholder Number of shares without selling restrictions held
Type of shares Quantity China Pharmaceutical Investment Co., Ltd. 108,418,487 RMB ordinary shares 108,418,487 ZHOU XIAOYAN 29,315,336 RMB ordinary shares 29,315,336 Liu Xi 16,753,419 RMB ordinary shares 16,753,419 Cheng Hui 14,349,483 RMB ordinary shares 14,349,483 Luo Aiping 14,244,444 RMB ordinary shares 14,244,444 Sun Xiaolin 12,597,863 RMB ordinary shares 12,597,863 Zou Zuojun 9,820,165 RMB ordinary shares 9,820,165 #Liu Shaoluan 6,431,885 RMB ordinary shares 6,431,885 Chen Hui 4,930,000 RMB ordinary shares 4,930,000 Hong Kong Securities Clearing Company Limited 3,347,982 RMB ordinary shares 3,347,982 There are 3,544,084 shares in the special repurchase securities account of Beijing Jiuqiang Biotechnology Co., Ltd.
Explanation of the related relationships or concerted actions of the shareholders China Pharmaceutical Investment Co., Ltd., Liu Xi, Luo Aiping, Sun Xiaolin, Zou Zuojun, and the above shareholders
There is no related relationship between ZHOU XIAOYAN and Cheng Hui, and they are not persons acting in concert; the company does not know whether there is any related relationship between other shareholders, nor whether they are acting in concert.
Moving.
Description of the top 10 shareholders participating in the margin trading and securities lending business (for example, shareholder #Liu Shaoluan holds 6,431,885 shares through an investor credit securities account) and holds 0 shares through an ordinary securities account.
The situation of shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participating in the refinancing business and lending shares
□Applicable Not applicable
The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning.
□Applicable Not applicable
(2) Total number of preferred shareholders of the company and shareholding status of the top 10 preferred shareholders
□Applicable Not applicable
(3) Changes in restricted shares
Applicable □Not applicable
Unit: Share
Restrictions on sales are lifted in this period. Restrictions on sales are added in this period. Name of shareholder on the date when restrictions on sales are to be lifted. Number of shares subject to restrictions on sales at the beginning of the period. Number of shares subject to restrictions on sales at the end of the period. Reasons for restrictions on sales.
Number of shares Number of shares The period is based on the number of shares before expiration.
Resign before expiry
Shuanghe 39,222 9,806 0 29,416 Any senior executive locks the shares and the manager locks the shares
The provisions of unlocking
Lin Qixin locked by senior executives 78,475 0 39,238 117,713 Shares locked by senior executives
Share provisions unlocked
According to executive lock Wang Jianmin 194,668 0 29,428 224,096 Executive lock shares
Share provisions unlocked
According to executives locking Yang Qinghai 70,217 0 35,034 105,251 shares locked by executives
Total required unlocking of shares 382,582 9,806 103,700 476,476 -- --
3. Other important matters
□Applicable Not applicable
Beijing Jiuqiang Biotechnology Co., Ltd. 2026 First Quarter Report
4. Quarterly Financial Statements
(1) Financial statements
- Consolidated balance sheet
Prepared by: Beijing Jiuqiang Biotechnology Co., Ltd.
March 31, 2026
Unit: Yuan
Item Ending balance Beginning balance
Current assets:
Monetary funds 673,345,483.11 539,645,136.36 Settlement reserves
Loan funds
trading financial assets
Derivative financial assets
Notes receivable 20,213,276.78 21,617,877.22 Accounts receivable 1,050,105,000.23 1,009,808,970.34 Accounts receivable financing
Prepayments 30,963,192.18 22,043,463.77 Premiums receivable
Reinsurance accounts receivable
Receivable reinsurance contract reserves
Other receivables 10,692,769.73 10,222,149.03 Including: interest receivable
Dividends receivable
Buy financial assets under resale agreements
Inventory 189,031,969.49 187,113,863.10
Among them: data resources
contract assets
Assets held for sale
Non-current assets due within one year 370,544,797.56 353,724,779.22 Other current assets 3,649,643.53 55,515,461.22 Total current assets 2,348,546,132.61 2,199,691,700.26 Non-current assets:
Grant loans and advances
debt investment
Other debt investments
Long-term receivables 4,507,817.00 4,592,327.00 Long-term equity investment 59,694,166.50 60,739,941.04 Other equity instrument investments 30,000,000.00 30,000,000.00 Other non-current financial assets
Investment real estate 21,797,390.58 22,418,489.19 Fixed assets 526,364,259.00 540,211,513.15 Construction in progress 0.00 0.00 Productive biological assets
oil and gas assets
Right-of-use assets 5,424,653.72 5,790,537.61 Intangible assets 53,111,181.31 56,063,563.97
Among them: data resources
development expenditure
Among them: data resources
Goodwill 1,497,772,975.19 1,497,772,975.19 Long-term deferred expenses 1,421,849.89 1,533,856.13
Beijing Jiuqiang Biotechnology Co., Ltd. 2026 First Quarter Report
Deferred income tax assets 43,463,321.51 43,434,517.42 Other non-current assets 591,157,486.83 590,181,772.53 Total non-current assets 2,834,715,101.53 2,852,739,493.23 Total assets 5,183,261,234.14 5,052,431,193.49 Current liabilities:
Short-term borrowings 75,721.14 64,515.95 Borrowings from the central bank
borrowing funds
Trading financial liabilities
Derivative financial liabilities
Notes payable
Accounts payable 45,489,657.12 51,932,740.52 Advance receipts 3,095,537.66 4,012,808.27 Contract liabilities 22,790,270.18 11,290,208.06 Financial assets sold under repurchase
Taking deposits and placing deposits with other banks
Agent for buying and selling securities
Agent underwriting securities funds
Employee benefits payable 13,680,736.23 41,324,197.12 Taxes payable 48,136,148.36 39,073,849.53 Other payables 34,156,084.64 4,294,868.57 Including: interest payable
Dividends payable
Handling fees and commissions payable
Reinsurance accounts payable
Liabilities held for sale
Non-current liabilities due within one year 13,874,549.01 9,681,939.15 Other current liabilities 11,570,844.61 9,641,350.23 Total current liabilities 192,869,548.95 171,316,477.40 Non-current liabilities:
insurance contract reserves
Long-term borrowings 0.00 0.00 Bonds payable 1,072,058,043.67 1,063,887,404.28 Including: preference shares
perpetual bond
Lease liabilities 3,966,707.23 4,084,131.01 Long-term payables
Long-term employee benefits payable
Estimated liabilities
Deferred income 22,950,995.18 24,051,166.29 Deferred income tax liabilities 5,922,959.70 6,232,296.18 Other non-current liabilities
Total non-current liabilities 1,104,898,705.78 1,098,254,997.76 Total liabilities 1,297,768,254.73 1,269,571,475.16 Owners’ equity:
Share capital 586,308,628.00 586,308,628.00 Other equity instruments 148,530,312.38 148,530,312.38 Including: preference shares
perpetual bond
Capital reserve 345,404,040.45 347,383,593.45 Less: treasury shares 57,841,897.72 57,841,897.72 Other comprehensive income 43,956.94 297,912.88 Special reserves
Surplus reserve 295,104,897.75 295,104,897.75 General risk reserve
Undistributed profits 2,573,839,393.31 2,468,232,036.98
Beijing Jiuqiang Biotechnology Co., Ltd. 2026 First Quarter Report
Total owners’ equity attributable to the parent company 3,891,389,331.11 3,788,015,483.72
Minority shareholders' equity -5,896,351.70 -5,155,765.39Total owners' equity 3,885,492,979.41 3,782,859,718.33Total liabilities and owners' equity 5,183,261,234.14 5,052,431,193.49Legal representative: Zou Zuojun Person in charge of accounting work: Liu Wei Person in charge of accounting department: Liu Wei
Beijing Jiuqiang Biotechnology Co., Ltd. 2026 First Quarter Report
- Consolidated income statement
Unit: Yuan
Item Amount for the current period Amount for the previous period
- Total operating income 334,810,688.09 319,809,793.71 Including: operating income 334,810,688.09 319,809,793.71 Interest income
Premiums earned
Fee and commission income
- Total operating costs 217,562,849.44 222,735,370.83 Including: operating costs 60,471,472.54 61,274,484.14 Interest expenses
Handling fees and commission expenses
surrender deposit
Net compensation expenses
Net withdrawal of insurance liability reserves
policy dividend payout
Reinsurance cost
Taxes and surcharges 5,334,191.44 4,692,611.19 Sales expenses 70,780,689.37 70,629,979.65 Management expenses 29,497,452.78 33,184,583.42 Research and development expenses 40,550,434.48 43,006,922.56Financial expenses 10,928,608.83 9,946,789.87Including: Interest expenses 12,439,357.20 11,942,974.95
Interest income 1,197,377.59 2,630,778.07 plus: other income 3,106,311.02 1,884,693.31 investment income (losses are filled in with "-"
3,665,217.16 -152,998.11 columns)
Of which: for associates and joint ventures
corporate investment income
Measured at amortized cost
Income from derecognition of financial assets
Exchange gains (losses are filled in with "-"
column)
Net exposure hedging gain (loss calculated as
Fill in the column with "-" sign)
Gains from changes in fair value (losses calculated as
Fill in the column with "-" sign)
Credit impairment losses (losses are marked with "-"
0.00 483.30 fill in the column)
Asset impairment losses (losses are marked with "-"
0.00 0.00 fill in the column)
Asset disposal income (losses are marked with "-"
-77,063.71 -750,180.00 fill in the column)
3. Operating profit (loss is filled in with "-"
123,942,303.12 98,056,421.38 columns)
Add: Non-operating income 46,413.88 12,347.51 Less: Non-operating expenses 4,378.53 44,715.92
- Total profits (total losses are represented by "-" 123,984,338.47 98,024,052.97
Beijing Jiuqiang Biotechnology Co., Ltd. 2026 First Quarter Report
Fill in the column)
Less: Income tax expenses 18,373,065.47 14,451,437.68
5. Net profit (net loss is filled in with "-"
105,611,273.00 83,572,615.29 columns)
(1) Classification by business continuity
- Net profit from continuing operations (net loss divided by
105,611,273.00 83,572,615.29 (Fill in “-”)
- Net profit from discontinued operations (net loss equal to
Fill in the column with "-" sign)
(2) Classification according to ownership ownership
Net profit attributable to owners of the parent company 105,607,356.33 83,257,495.41
Profit and loss of minority shareholders 3,916.67 315,119.88
Net after-tax other comprehensive income -338,607.92 -35,824.27 Other comprehensive income attributable to owners of the parent company
-253,955.94 -27,990.36 net amount after tax
(1) Others that cannot be reclassified into profit or loss
Comprehensive income
- Remeasure changes in defined benefit plans
Um
- Others that cannot be transferred to profit or loss under the equity method
Comprehensive income
- Fair value of other equity instrument investments
change
- Fair value of the company’s own credit risk
change
5.Others
(2) Other comprehensive items that will be reclassified into profit or loss
-253,955.94 -27,990.36 combined income
- Other comprehensive items that can be transferred to profits and losses under the equity method
combined income
Changes in fair value of other debt investments
Financial assets are reclassified into other comprehensive
Amount of combined income
Credit impairment provisions for other debt investments
Cash flow hedging reserve
Translation difference of foreign currency financial statements -253,955.94 -27,990.36
7.Others
Other comprehensive income attributable to minority shareholders
-84,651.98 -7,833.91 Net after tax
- Total comprehensive income 105,272,665.08 83,536,791.02 Total comprehensive income attributable to owners of the parent company
105,353,400.39 83,229,505.05 amount
Total comprehensive income attributable to minority shareholders -80,735.31 307,285.97
8. Earnings per share:
(1) Basic earnings per share 0.18 0.14
(2) Diluted earnings per share 0.18 0.14 If a business merger under the same control occurs in this period, the net profit realized by the merged party before the merger is: 0.00 yuan, and the net profit realized by the merged party in the previous period is: 0.00 yuan. Legal representative: Zou Zuojun Person in charge of accounting work: Liu Wei Person in charge of accounting department: Liu Wei
Beijing Jiuqiang Biotechnology Co., Ltd. 2026 First Quarter Report
- Consolidated cash flow statement
Unit: Yuan
Item Amount for the current period Amount for the previous period
1. Cash flow generated from operating activities:
Cash received from sales of goods and provision of services 336,831,910.18 361,407,329.32 Net increase in customer deposits and deposits from banks
Net increase in borrowing from the central bank
Net increase in borrowing funds from other financial institutions
Cash received from premiums from the original insurance contract
Net cash received from reinsurance business
Net increase in policyholders’ savings and investment funds
Cash collected from interest, fees and commissions
Net increase in borrowing funds
Net increase in repurchase business funds
Net cash received from buying and selling securities on behalf of agents
tax refund received
Other cash received related to operating activities 5,189,089.54 5,000,228.60 Subtotal of cash inflows from operating activities 342,020,999.72 366,407,557.92 Cash paid for purchasing goods and receiving services 67,502,608.49 75,496,196.47 Net increase in customer loans and advances
Net increase in deposits with central banks and inter-banks
Cash used to pay compensation from the original insurance contract
Net increase in lending funds
Cash payments for interest, fees and commissions
Cash payment for policy dividends
Cash paid to and for employees 100,262,384.08 136,531,353.97 Various taxes paid 46,519,357.94 43,495,060.14 Other cash paid related to operating activities 32,230,412.45 39,938,232.83 Subtotal cash outflow from operating activities 246,514,762.96 295,460,843.41 Net cash flow generated from operating activities 95,506,236.76 70,946,714.51
2. Cash flow generated from investing activities:
Cash received from recovery of investment 50,000,000.00 79,870,000.00 Cash received from investment income 325,000.00 8,646,222.24 Disposal of fixed assets, intangible assets and other long-term assets
5,700.00 Net cash amount recovered from assets in period 86,744.00
Received from disposal of subsidiaries and other business units
net cash
Other cash received related to investing activities
Subtotal of cash inflows from investing activities 50,330,700.00 88,602,966.24 Purchase and construction of fixed assets, intangible assets and other long-term assets
9,107,025.68 17,138,675.41 Cash paid for assets
Cash paid for investment 120,000,000.00 Net increase in pledged loans
Obtain payment from subsidiaries and other business units
net cash
Other cash payments related to investing activities
Subtotal of cash outflows from investing activities 9,107,025.68 137,138,675.41 Net cash flow generated from investing activities 41,223,674.32 -48,535,709.17
3. Cash flow generated from financing activities:
Absorbing cash received from investments
Beijing Jiuqiang Biotechnology Co., Ltd. 2026 First Quarter Report
Among them: subsidiaries absorb investment from minority shareholders
cash received
Cash received from borrowing 355,177.09 470,716.28
Other cash received related to financing activities 284,149.33 Subtotal of cash inflows from financing activities 355,177.09 754,865.61 Cash paid to repay debts 342,967.74 537,445.54 Payments to distribute dividends, profits or repay interest
2,639,404.00 3,200,279.27 cash
Including: Payments made by subsidiaries to minority shareholders
2,639,404.00 3,011,064.00 Dividends and profits
Payment of other cash related to financing activities 208,312.20 265,081.60 Subtotal of cash outflows from financing activities 3,190,683.94 4,002,806.41 Net cash flow generated from financing activities -2,835,506.85 -3,247,940.80
4. The impact of exchange rate changes on cash and cash equivalents
-194,057.48 -31,821.43 impact
- Net increase in cash and cash equivalents 133,700,346.75 19,131,243.11
Add: Balance of cash and cash equivalents at the beginning of the period 539,645,136.36 1,042,657,721.31
- Balance of cash and cash equivalents at the end of the period 673,345,483.11 1,061,788,964.42
Beijing Jiuqiang Biotechnology Co., Ltd. 2026 First Quarter Report
(2) Adjustment of relevant items in the financial statements at the beginning of the year when the new accounting standards are first implemented starting from 2026
□Applicable Not applicable
(3) Audit report
Whether the first quarter financial accounting report has been audited
□Yes No
The company's first quarter financial accounting report has not been audited.
Board of Directors of Beijing Jiuqiang Biotechnology Co., Ltd.
April 27, 2026